KRYS Krystal Biotech Inc

Price (delayed)

$59.47

Market cap

$1.32B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.13

Enterprise value

$922.21M

Highlights
Krystal Biotech's equity has surged by 117% YoY and by 47% QoQ
The company's quick ratio has surged by 151% QoQ but it fell by 4% YoY
The net income has plunged by 110% YoY and by 33% from the previous quarter
The EPS has plunged by 72% YoY and by 25% from the previous quarter

Key stats

What are the main financial stats of KRYS
Market
Shares outstanding
22.2M
Market cap
$1.32B
Enterprise value
$922.21M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.06
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$41.15M
EBITDA
-$39.12M
Free cash flow
-$45.32M
Per share
EPS
-$2.13
Free cash flow per share
-$2.13
Book value per share
$19.4
Revenue per share
$0
TBVPS
$20.84
Balance sheet
Total assets
$443.02M
Total liabilities
$12.37M
Debt
$3.87M
Equity
$430.65M
Working capital
$396.68M
Liquidity
Debt to equity
0.01
Current ratio
44.38
Quick ratio
44.12
Net debt/EBITDA
10.18
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-12.3%
Return on equity
-12.8%
Return on invested capital
-142.6%
Return on capital employed
-9.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KRYS stock price

How has the Krystal Biotech stock price performed over time
Intraday
4.96%
1 week
-0.63%
1 month
-15.04%
1 year
46.91%
YTD
-0.88%
QTD
-12.54%

Financial performance

How have Krystal Biotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$41.41M
Net income
-$42.64M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 110% YoY and by 33% from the previous quarter
The operating income has plunged by 77% YoY and by 25% from the previous quarter

Growth

What is Krystal Biotech's growth rate over time

Valuation

What is Krystal Biotech stock price valuation
P/E
N/A
P/B
3.06
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 72% YoY and by 25% from the previous quarter
Krystal Biotech's equity has surged by 117% YoY and by 47% QoQ
KRYS's P/B is 12% below its last 4 quarters average of 3.3

Efficiency

How efficient is Krystal Biotech business performance
Krystal Biotech's return on invested capital has decreased by 45% YoY and by 15% QoQ
The ROE has contracted by 27% YoY and by 9% from the previous quarter
Krystal Biotech's ROA has decreased by 26% YoY and by 10% from the previous quarter

Dividends

What is KRYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRYS.

Financial health

How did Krystal Biotech financials performed over time
The company's quick ratio has surged by 151% QoQ but it fell by 4% YoY
The current ratio has surged by 149% since the previous quarter but it has declined by 4.3% year-on-year
The debt is 99% less than the equity
Krystal Biotech's equity has surged by 117% YoY and by 47% QoQ
The debt to equity has plunged by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.